REPARE THERAPEUTICS INC

Repare Therapeutics Inc. (http://www.reparerx.com/) is a clinical-stage precision oncology company. The Company is focused on the development of synthetic lethality (SL) based therapies to patients with cancer. It uses genome wide, SNIPRx platform to systematically discover and develop targeted cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company is developing its pipeline of SL product candidates, including its lead product candidate, RP-3500, a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related (ATR) protein kinase for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated (ATM) kinase gene. Its preclinical programs include RP-6306 Protein Kinase Membrane-associated tYrosine- and Threonine- specific cdc-2 inhibitory (PKMYT1)kinase SL inhibitor, in advanced solid tumors.

• REPARE THERAPEUTICS INC